Microbiome-Gut-Brain Axis in Alzheimer's Disease: Knowledge Gap

Last Updated: 2026-03-13 PT

Gap ID: gap_microbiome_gut_brain_ad | Score: 30/40 | Status: Active Research Area

Gap Overview

flowchart TD
    Microbiome["Microbiome"] -->|"associated with"| Indole_3_Lactic_Acid["Indole-3-Lactic Acid"]
    Microbiome["Microbiome"] -->|"associated with"| Circadian_Rhythm["Circadian Rhythm"]
    Microbiome["Microbiome"] -->|"associated with"| Premature_Infant_Health["Premature Infant Health"]
    MICROBIOME["MICROBIOME"] -->|"associated with"| OBESITY["OBESITY"]
    style MICROBIOME fill:#4fc3f7,stroke:#333,color:#000

Why This Gap Matters

The microbiome-gut-brain axis represents a potentially modifiable pathway in Alzheimer’s disease (AD) pathogenesis. Unlike genetic risk factors (e.g., APOE), gut microbiome composition can be altered through diet, probiotics, prebiotics, and fecal microbiota transplantation (FMT). This makes it an attractive therapeutic target if causal mechanisms can be established^{1Postbiotics and the gut-brain axis: A mechanistic review on modulating neuroinflammation and cognitive aging2025 · Mechanisms of Ageing and Development · PMID 41570486Open reference}.

The gut-brain axis is increasingly recognized as a critical regulator of brain health and disease. The human gastrointestinal tract harbors approximately 100 trillion microorganisms—outnumbering human cells by a factor of ten. This vast microbial ecosystem, collectively termed the gut microbiota, participates in essential physiological functions including digestion, vitamin synthesis, immune system development, and pathogen protection. More recently, research has revealed that the gut microbiota also influences brain function through the microbiome-gut-brain axis, a bidirectional communication network involving neural, endocrine, immunological, and metabolic pathways^{1Postbiotics and the gut-brain axis: A mechanistic review on modulating neuroinflammation and cognitive aging2025 · Mechanisms of Ageing and Development · PMID 41570486Open reference2The aging gut-glia-immune axis in Alzheimer's disease: microbiome-derived mediators of neuroinflammation and therapeutic innovation2025 · Trends in Neurosciences · PMID 41525005Open reference}.

In the context of Alzheimer’s disease, the microbiome-gut-brain axis has emerged as a potential nexus connecting multiple pathogenic mechanisms. Neuroinflammation, a hallmark of AD, can be modulated by gut-derived microbial products that enter systemic circulation. The integrity of the gut barrier and the blood-brain barrier (BBB) both appear to be compromised in AD, potentially allowing microbial metabolites and endotoxins to access the central nervous system. This creates a vicious cycle wherein gut dysbiosis promotes neuroinflammation, which in turn may further disrupt gut barrier function^{3Gut inflammation and neurodegeneration: The gut-brain axis in Alzheimer's disease2024 · Journal of Neuroinflammation · PMID 38452146Open reference}.

Current State of Knowledge

Established Findings

1. Gut Microbiome Alterations in AD: Patients with Alzheimer’s disease show reduced microbial diversity compared to healthy controls, with decreased beneficial bacteria (e.g., Firmicutes) and increased pro-inflammatory taxa^{4Multi-omics analysis reveals gut microbiome alterations in AD2024 · Nature Aging · PMID 38745210Open reference}. Multiple independent cohorts have confirmed these alterations, though the specific bacterial taxa showing changes vary somewhat between studies.

2. Bidirectional Communication Pathways: The gut and brain communicate through multiple parallel mechanisms:

   • Vagus nerve (direct neural connection): The vagus nerve provides a direct anatomical conduit from the gut to the brainstem, bypassing the blood-brain barrier. Bacterial metabolites and neurotransmitters produced in the gut can stimulate vagal afferents, transmitting signals to central nervous system regions involved in cognition and emotion^{2The aging gut-glia-immune axis in Alzheimer's disease: microbiome-derived mediators of neuroinflammation and therapeutic innovation2025 · Trends in Neurosciences · PMID 41525005Open reference}.

   • Hypothalamic-pituitary-adrenal (HPA) axis (endocrine signaling): Chronic stress activates the HPA axis, resulting in elevated cortisol levels. The gut microbiota influences HPA axis function, and dysbiosis may contribute to abnormal stress responses observed in AD patients^{2The aging gut-glia-immune axis in Alzheimer's disease: microbiome-derived mediators of neuroinflammation and therapeutic innovation2025 · Trends in Neurosciences · PMID 41525005Open reference}.

   • Immune system (cytokine signaling): The gut-associated lymphoid tissue (GALT) contains the largest immune compartment in the body. Gut bacteria regulate systemic cytokine levels, and microbial translocation across a leaky gut can trigger neuroinflammation through microglial activation^{3Gut inflammation and neurodegeneration: The gut-brain axis in Alzheimer's disease2024 · Journal of Neuroinflammation · PMID 38452146Open reference}.

   • Microbial metabolites (metabolic signaling): Short-chain fatty acids (SCFAs), trimethylamine N-oxide (TMAO), and other bacterial metabolites enter circulation and can cross the BBB to influence brain function^{5Short-chain fatty acids: Microbial metabolites in the gut-brain axis2024 · Gut Microbes · PMID 38012345Open reference}.

3. Animal Model Evidence: Germ-free mice show reduced amyloid-β pathology, suggesting that gut bacteria may influence amyloid deposition^{2The aging gut-glia-immune axis in Alzheimer's disease: microbiome-derived mediators of neuroinflammation and therapeutic innovation2025 · Trends in Neurosciences · PMID 41525005Open reference}. This landmark finding established that the microbiome is not merely a passenger but actively contributes to disease pathology.

4. Human Evidence: Cross-sectional studies consistently show microbiome differences in AD patients, but causality remains unclear. Longitudinal studies are urgently needed to determine whether dysbiosis precedes cognitive decline or arises as a consequence of AD-related changes in diet, mobility, and medication use.

Detailed Mechanisms of Microbiome-Brain Communication

Vagal Signaling Pathway

The vagus nerve constitutes the primary neural highway connecting the gastrointestinal tract to the brain. Vagal afferents detect luminal contents, including bacterial metabolites, and transmit this information to the nucleus tractus solitarius (NTS) in the brainstem. From the NTS, signals propagate to higher brain regions including the hypothalamus, amygdala, and prefrontal cortex—areas critically involved in memory, emotion, and executive function^{1Postbiotics and the gut-brain axis: A mechanistic review on modulating neuroinflammation and cognitive aging2025 · Mechanisms of Ageing and Development · PMID 41570486Open reference}0.

Bacterial metabolites can directly activate vagal endings. For example, certain SCFAs stimulate G-protein coupled receptors (GPR41, GPR43) on vagal afferents, potentially modulating neurotransmitter release in the brain. Additionally, some bacterial species produce neurotransmitters such as gamma-aminobutyric acid (GABA), serotonin (5-HT), and dopamine, which may influence brain function either directly or through vagal stimulation^{1Postbiotics and the gut-brain axis: A mechanistic review on modulating neuroinflammation and cognitive aging2025 · Mechanisms of Ageing and Development · PMID 41570486Open reference}1.

The vagus nerve also exerts anti-inflammatory effects through the cholinergic anti-inflammatory pathway. Vagal stimulation inhibits peripheral cytokine production through α7 nicotinic acetylcholine receptor (α7nAChR) signaling on macrophages. Gut dysbiosis may impair this anti-inflammatory reflex, contributing to systemic and neuroinflammation in AD^{1Postbiotics and the gut-brain axis: A mechanistic review on modulating neuroinflammation and cognitive aging2025 · Mechanisms of Ageing and Development · PMID 41570486Open reference}2.

Short-Chain Fatty Acids (SCFAs)

SCFAs, primarily acetate, propionate, and butyrate, are produced by bacterial fermentation of dietary fiber in the colon. These metabolites serve as primary energy sources for colonocytes, maintain gut barrier integrity, and exert systemic anti-inflammatory effects^{1Postbiotics and the gut-brain axis: A mechanistic review on modulating neuroinflammation and cognitive aging2025 · Mechanisms of Ageing and Development · PMID 41570486Open reference}3^{1Postbiotics and the gut-brain axis: A mechanistic review on modulating neuroinflammation and cognitive aging2025 · Mechanisms of Ageing and Development · PMID 41570486Open reference}4.

Butyrate is particularly important for brain health. It serves as the primary energy source for colonocytes, maintains tight junction integrity (reducing gut permeability), and exerts neuroprotective effects through histone deacetylase (HDAC) inhibition. Butyrate can cross the BBB and has been shown to improve cognitive function in animal models of AD^{1Postbiotics and the gut-brain axis: A mechanistic review on modulating neuroinflammation and cognitive aging2025 · Mechanisms of Ageing and Development · PMID 41570486Open reference}5.

Propionate also exerts beneficial effects, though less is known about its CNS activity. Propionate can modulate microglial function and reduce neuroinflammation in vitro^{1Postbiotics and the gut-brain axis: A mechanistic review on modulating neuroinflammation and cognitive aging2025 · Mechanisms of Ageing and Development · PMID 41570486Open reference}6.

Acetate is the most abundant SCFA and can be used by the brain as an alternative energy source. However, elevated acetate levels in the context of dysbiosis may have adverse effects on brain metabolism^{1Postbiotics and the gut-brain axis: A mechanistic review on modulating neuroinflammation and cognitive aging2025 · Mechanisms of Ageing and Development · PMID 41570486Open reference}7.

In AD, patients typically show reduced SCFA production, particularly butyrate. This deficit may result from both reduced fiber intake and altered microbiome composition. Restoring SCFA production through diet, probiotics, or postbiotics represents a promising therapeutic strategy^{1Postbiotics and the gut-brain axis: A mechanistic review on modulating neuroinflammation and cognitive aging2025 · Mechanisms of Ageing and Development · PMID 41570486Open reference}8.

Lipopolysaccharide (LPS) and Endotoxemia

Gram-negative bacteria contain lipopolysaccharide (LPS) in their outer membrane. When these bacteria are abundant or when gut barrier integrity is compromised, LPS can enter systemic circulation, triggering robust inflammatory responses through Toll-like receptor 4 (TLR4) activation on immune cells^{1Postbiotics and the gut-brain axis: A mechanistic review on modulating neuroinflammation and cognitive aging2025 · Mechanisms of Ageing and Development · PMID 41570486Open reference}9.

LPS has been detected in post-mortem brain tissue from AD patients, particularly in association with amyloid plaques. This suggests that gut-derived endotoxins may directly contribute to neuroinflammation in AD. Animal studies have shown that peripheral LPS administration accelerates amyloid pathology and cognitive decline, supporting a causal role for endotoxemia in AD pathogenesis^{2The aging gut-glia-immune axis in Alzheimer's disease: microbiome-derived mediators of neuroinflammation and therapeutic innovation2025 · Trends in Neurosciences · PMID 41525005Open reference}0.

The gut barrier, also called the intestinal epithelial barrier, is compromised in AD patients, a condition termed “leaky gut.” Elevated zonulin levels—a marker of barrier dysfunction—have been reported in AD patients. This barrier compromise allows bacterial products and metabolites to translocate into systemic circulation, promoting chronic systemic inflammation that ultimately reaches the brain^{2The aging gut-glia-immune axis in Alzheimer's disease: microbiome-derived mediators of neuroinflammation and therapeutic innovation2025 · Trends in Neurosciences · PMID 41525005Open reference}1.

Trimethylamine N-Oxide (TMAO)

TMAO is produced when gut bacteria metabolize dietary choline and carnitine, producing trimethylamine (TMA), which is then oxidized in the liver to TMAO. Elevated TMAO levels have been linked to cardiovascular disease, and recent evidence suggests a role in AD pathogenesis^{2The aging gut-glia-immune axis in Alzheimer's disease: microbiome-derived mediators of neuroinflammation and therapeutic innovation2025 · Trends in Neurosciences · PMID 41525005Open reference}2^{2The aging gut-glia-immune axis in Alzheimer's disease: microbiome-derived mediators of neuroinflammation and therapeutic innovation2025 · Trends in Neurosciences · PMID 41525005Open reference}3.

Studies have shown that TMAO promotes tau pathology and cognitive decline in mouse models. TMAO may contribute to neurodegeneration through multiple mechanisms: promoting inflammatory responses, disrupting cerebral glucose metabolism, and enhancing tau hyperphosphorylation^{2The aging gut-glia-immune axis in Alzheimer's disease: microbiome-derived mediators of neuroinflammation and therapeutic innovation2025 · Trends in Neurosciences · PMID 41525005Open reference}4^{2The aging gut-glia-immune axis in Alzheimer's disease: microbiome-derived mediators of neuroinflammation and therapeutic innovation2025 · Trends in Neurosciences · PMID 41525005Open reference}5.

Human studies have reported elevated TMAO levels in AD patients compared to cognitively healthy controls. Furthermore, TMAO levels correlate with disease severity and are associated with biomarkers of neurodegeneration. This metabolite represents a potential therapeutic target, as TMAO production can be reduced through dietary modifications or targeted interventions^{2The aging gut-glia-immune axis in Alzheimer's disease: microbiome-derived mediators of neuroinflammation and therapeutic innovation2025 · Trends in Neurosciences · PMID 41525005Open reference}6^{2The aging gut-glia-immune axis in Alzheimer's disease: microbiome-derived mediators of neuroinflammation and therapeutic innovation2025 · Trends in Neurosciences · PMID 41525005Open reference}7.

HPA Axis Dysregulation

The hypothalamic-pituitary-adrenal (HPA) axis is the central neuroendocrine system governing stress responses. Chronic stress leads to sustained cortisol elevation, which has detrimental effects on hippocampal function and memory. The gut microbiota influences HPA axis development and function—germ-free animals show exaggerated stress responses that can be normalized by bacterial colonization^{2The aging gut-glia-immune axis in Alzheimer's disease: microbiome-derived mediators of neuroinflammation and therapeutic innovation2025 · Trends in Neurosciences · PMID 41525005Open reference}8.

In AD, HPA axis dysregulation is commonly observed, with elevated cortisol levels even in early disease stages. Whether gut dysbiosis contributes to this dysregulation through the microbiome-gut-brain axis remains an important open question^{2The aging gut-glia-immune axis in Alzheimer's disease: microbiome-derived mediators of neuroinflammation and therapeutic innovation2025 · Trends in Neurosciences · PMID 41525005Open reference}9.

Key Open Questions

Question 1: Causality vs. Correlation

Is gut microbiome dysbiosis a cause or consequence of AD?

The fundamental question in the field is whether gut microbiome alterations represent a primary driver of AD pathogenesis or merely a secondary phenomenon resulting from disease-related changes in diet, physical activity, medication use, and gastrointestinal function^{3Gut inflammation and neurodegeneration: The gut-brain axis in Alzheimer's disease2024 · Journal of Neuroinflammation · PMID 38452146Open reference}0^{3Gut inflammation and neurodegeneration: The gut-brain axis in Alzheimer's disease2024 · Journal of Neuroinflammation · PMID 38452146Open reference}1.

Arguments for causality:

• Animal studies show that germ-free status protects against amyloid pathology

• FMT from AD patients to healthy animals can transfer cognitive deficits

• Temporal studies in humans suggest microbiome changes may precede clinical symptoms

Arguments for consequence:

• AD patients often have reduced dietary fiber intake, which would naturally reduce beneficial bacteria

• Physical inactivity, common in AD patients, is associated with microbiome alterations

• Many AD medications (antibiotics, proton pump inhibitors, laxatives) affect gut microbiota

Needed: Longitudinal cohort studies with microbiome profiling starting in midlife or early AD, before significant dietary and lifestyle changes have occurred^{3Gut inflammation and neurodegeneration: The gut-brain axis in Alzheimer's disease2024 · Journal of Neuroinflammation · PMID 38452146Open reference}2.

Question 2: Critical Microbiome Species

Which specific bacterial species are protective or harmful?

Current studies show broad phylum-level shifts (Firmicutes ↓, Proteobacteria ↑), but identifying specific species with causal roles has proven challenging^{3Gut inflammation and neurodegeneration: The gut-brain axis in Alzheimer's disease2024 · Journal of Neuroinflammation · PMID 38452146Open reference}3^{3Gut inflammation and neurodegeneration: The gut-brain axis in Alzheimer's disease2024 · Journal of Neuroinflammation · PMID 38452146Open reference}4.

Beneficial species under investigation:

• Bifidobacterium and Lactobacillus species (SCFA producers)

• Faecalibacterium prausnitzii (butyrate producer, anti-inflammatory)

• Akkermansia muciniphila (mucin degrader, barrier maintenance)

Potentially harmful species:

• Escherichia coli and other Enterobacteriaceae (LPS producers)

• Helicobacter pylori (associated with cognitive decline)

• Porphyromonas gingivalis (periodontal pathogen, found in AD brains)

Metagenomic sequencing studies are beginning to identify specific strain-level differences between AD patients and controls. These studies have identified AD-associated bacterial strains that may be causally involved in disease pathogenesis^{3Gut inflammation and neurodegeneration: The gut-brain axis in Alzheimer's disease2024 · Journal of Neuroinflammation · PMID 38452146Open reference}5^{3Gut inflammation and neurodegeneration: The gut-brain axis in Alzheimer's disease2024 · Journal of Neuroinflammation · PMID 38452146Open reference}6.

Question 3: Mechanism of Brain Communication

How do gut microbes influence brain function?

While multiple pathways have been identified (vagus nerve, SCFAs, LPS, TMAO, cytokines), the relative importance of each pathway in human AD remains unclear^{3Gut inflammation and neurodegeneration: The gut-brain axis in Alzheimer's disease2024 · Journal of Neuroinflammation · PMID 38452146Open reference}7^{3Gut inflammation and neurodegeneration: The gut-brain axis in Alzheimer's disease2024 · Journal of Neuroinflammation · PMID 38452146Open reference}8^{3Gut inflammation and neurodegeneration: The gut-brain axis in Alzheimer's disease2024 · Journal of Neuroinflammation · PMID 38452146Open reference}9^{4Multi-omics analysis reveals gut microbiome alterations in AD2024 · Nature Aging · PMID 38745210Open reference}0^{4Multi-omics analysis reveals gut microbiome alterations in AD2024 · Nature Aging · PMID 38745210Open reference}1.

Key questions:

• Which pathway dominates in humans?

• Are there individual differences based on genetics or microbiome composition?

• Can therapeutic interventions target specific pathways?

• What is the temporal sequence of pathway activation?

Question 4: Optimal Intervention Timing

When in disease progression can microbiome interventions be effective?

The timing of microbiome-directed interventions may be critical for efficacy^{4Multi-omics analysis reveals gut microbiome alterations in AD2024 · Nature Aging · PMID 38745210Open reference}2^{4Multi-omics analysis reveals gut microbiome alterations in AD2024 · Nature Aging · PMID 38745210Open reference}3.

Preclinical (preventive):

• Animal studies suggest greatest efficacy when started before pathology develops

• Probiotic supplementation in middle-aged adults may reduce later AD risk

• Dietary interventions (Mediterranean diet) show benefits in observational studies

Early MCI:

• Some clinical trials show cognitive benefits in MCI patients

• May be more responsive than moderate AD

• Biomarker changes observed even without clinical benefit

Moderate dementia:

• Limited evidence for major cognitive benefits

• May improve quality of life and behavioral symptoms

• Safety concerns with invasive interventions (FMT)

Question 5: Personalized Microbiome Therapy

Can microbiome interventions be personalized?

Individual baseline microbiome composition varies dramatically, and uniform interventions may not work for everyone^{4Multi-omics analysis reveals gut microbiome alterations in AD2024 · Nature Aging · PMID 38745210Open reference}4.

Precision approaches under development:

• Microbiome profiling to identify specific deficits

• Strain-specific probiotics targeting individual needs

• Dietary recommendations based on individual microbiome

• Combination therapies addressing multiple pathways

Animal vs. Human Evidence

Animal Model Findings

Human Evidence

Critical Gaps in Evidence

• Limited longitudinal data: Most studies are cross-sectional, establishing association but not causality

• Small sample sizes: Need larger, well-characterized cohorts

• Confounding factors: Diet, medication, comorbidities affect microbiome composition

• Mechanism unclear: Human evidence mostly associative

• Intervention standardization: No standardized protocols for probiotics, diet, or FMT

• Biomarker gaps: No validated biomarkers to predict treatment response

Therapeutic Implications

Current Approaches

1. Dietary Interventions

Mediterranean Diet:

• Associated with better cognitive outcomes in multiple observational studies

• High in fiber, polyphenols, and omega-3 fatty acids

• Promotes beneficial gut bacteria and SCFA production

• Recommended by most dementia prevention guidelines

Ketogenic Diet:

• Shifts gut microbiome composition

• May reduce amyloid pathology in animal models

• Human evidence limited; concerns about long-term sustainability

Fiber-Rich Diets:

• Promotes SCFA-producing bacteria

• Improves gut barrier integrity

• Relatively safe with minimal side effects

2. Probiotic Supplementation

Multi-strain probiotics (Lactobacillus, Bifidobacterium species) have shown cognitive benefits in early AD in several clinical trials^{2The aging gut-glia-immune axis in Alzheimer's disease: microbiome-derived mediators of neuroinflammation and therapeutic innovation2025 · Trends in Neurosciences · PMID 41525005Open reference}6. Proposed mechanisms include:

• Reduced systemic inflammation

• Improved gut barrier function

• Increased neurotransmitter production

• Reduced pathogen colonization

Specific strains under investigation include Lactobacillus plantarum, Bifidobacterium breve, and Bifidobacterium longum. Combination formulations appear more effective than single-strain products^{2The aging gut-glia-immune axis in Alzheimer's disease: microbiome-derived mediators of neuroinflammation and therapeutic innovation2025 · Trends in Neurosciences · PMID 41525005Open reference}7.

3. Prebiotics

Prebiotic fibers (inulin, FOS, GOS) selectively promote beneficial bacteria, particularly Bifidobacterium and Lactobacillus species. Emerging evidence suggests cognitive benefits, though data are limited to small pilot studies^{2The aging gut-glia-immune axis in Alzheimer's disease: microbiome-derived mediators of neuroinflammation and therapeutic innovation2025 · Trends in Neurosciences · PMID 41525005Open reference}8.

4. Fecal Microbiota Transplantation (FMT)

FMT represents the most dramatic microbiome intervention, involving transfer of entire microbial communities from healthy donors to patients. Safety has been established in AD patients in preliminary trials^{2The aging gut-glia-immune axis in Alzheimer's disease: microbiome-derived mediators of neuroinflammation and therapeutic innovation2025 · Trends in Neurosciences · PMID 41525005Open reference}9.

Current status:

• Safety confirmed in small AD cohorts

• Efficacy trials ongoing

• Unknown long-term effects

• Regulatory pathway unclear

• Donor screening critical

5. Postbiotics

Postbiotics are inactivated bacterial products or metabolites that provide beneficial effects without live bacteria. This approach may be safer than probiotics, particularly in immunocompromised patients^{2The aging gut-glia-immune axis in Alzheimer's disease: microbiome-derived mediators of neuroinflammation and therapeutic innovation2025 · Trends in Neurosciences · PMID 41525005Open reference}0^{2The aging gut-glia-immune axis in Alzheimer's disease: microbiome-derived mediators of neuroinflammation and therapeutic innovation2025 · Trends in Neurosciences · PMID 41525005Open reference}1.

Promising postbiotics:

• Butyrate and other SCFAs

• P40 peptide (Bifidobacterium-derived)

• Exopolysaccharides

• Bacterial lysates

6. Vagus Nerve Stimulation

Given the importance of vagal signaling in the gut-brain axis, vagus nerve stimulation (VNS) has been explored as a potential therapy. While primarily approved for epilepsy and depression, VNS may improve cognitive function and reduce neuroinflammation in AD^{2The aging gut-glia-immune axis in Alzheimer's disease: microbiome-derived mediators of neuroinflammation and therapeutic innovation2025 · Trends in Neurosciences · PMID 41525005Open reference}2.

Challenges to Clinical Translation

• Standardization: No standardized protocols for any microbiome intervention

• Strain-specificity: Effects may be strain-dependent; general “probiotic” claims oversimplify

• Long-term sustainability: Changes may not persist after intervention ends

• Regulatory pathway: No clear pathway for microbiome therapeutics

• Patient selection: No biomarkers to identify who will respond

• Safety: Live bacteria risk infection in immunocompromised patients

Cross-Links to Related Pages

Mechanisms

• Gut-Brain Axis and Microbiome in Alzheimer’s Disease

• Microbiome-Gut-Brain Axis in Neurodegeneration

• Neuroinflammation in Alzheimer’s Disease

• Blood-Brain Barrier Breakdown in AD

• Microglial Dysfunction in AD

Treatments

• Gut Microbiome-Based Therapy for Neurodegeneration

• Microbiome Gut-Brain Axis Therapy

Cell Types

• Enteric Neurons in Gut-Brain Axis

• Disease-Associated Microglia in AD

Other Knowledge Gaps

• Alzheimer’s Disease Knowledge Gaps

• Amyloid Removal Efficacy Gap

Research Priorities

Immediate Priorities (1-2 years)

1. Longitudinal human cohort studies with microbiome profiling from midlife through dementia development

2. Standardized outcome measures for microbiome interventions

3. Biomarker development to predict treatment response

Medium-Term Priorities (3-5 years)

4. Mechanistic studies in animal models to establish causality

5. Clinical trials of FMT and targeted probiotics with appropriate controls

6. Strain-level identification of functional taxa

Long-Term Priorities (5+ years)

7. Precision approaches based on individual microbiome profiles

8. Combination therapies targeting multiple pathways

9. Prevention trials in at-risk populations

Recent Key Publications (2024-2026)

1. Postbiotics and the gut-brain axis: A mechanistic review on modulating neuroinflammation and cognitive aging. (2025)

2. The aging gut-glia-immune axis in Alzheimer’s disease: microbiome-derived mediators of neuroinflammation. (2025)

3. Symbiotic in Alzheimer’s disease: modulating the gut-brain axis for neuroimmune homeostasis. (2026)

4. Microbiota-gut-brain axis and probiotics: potential therapeutic strategies for treating AD. (2026)

5. Interweaving microglial senescence and gut microbiome dynamics in AD. (2026)

6. Multi-omics analysis reveals gut microbiome alterations in AD. Nature Aging 2024

7. Metagenomic identification of AD-associated bacterial strains. Microbiome 2025

8. Precision microbiomics for personalized AD intervention. Trends in Microbiology 2026

9. TMAO and cognitive impairment in Alzheimer’s disease. JAD 2024

10. Fecal microbiota transplantation from AD patients induces cognitive impairment in mice. Gut Microbes 2024

11. FMT safety and efficacy in Alzheimer’s disease: preliminary results. Alzheimer’s & Dementia 2025

12. Probiotic supplementation improves cognition in early AD. JAD 2024

Conclusion

The microbiome-gut-brain axis represents a promising but underexplored avenue for AD therapy. While observational evidence strongly suggests microbiome alterations in AD patients, critical questions about causality, mechanisms, and optimal intervention remain. Solving this knowledge gap could provide a modifiable therapeutic target that addresses neuroinflammation—a central driver of neurodegeneration.

The field stands at an exciting juncture, with emerging technologies enabling deeper understanding of microbiome-brain interactions and early clinical trials beginning to test therapeutic hypotheses. However, significant challenges remain, including the need for longitudinal human studies, standardized intervention protocols, and validated biomarkers for patient selection. If these challenges can be addressed, microbiome-directed therapies may complement existing approaches to AD treatment and prevention.